Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study

Autor: Vincenzo Nasillo, Elisabetta Lugli, Valeria Pioli, Laura Arletti, Paola Bresciani, Monica Maccaferri, Valeria Coluccio, Elisabetta Colaci, Mario Luppi, Andrea Messerotti, G. Ceccherelli, Maria Teresa Mariano, Angela Cuoghi, Ambra Paolini, Ivana Lagreca, Franco Narni, Chiara Quadrelli, Valeria Fantuzzi, Daniele Campioli, Giovanni Riva, Andrea Gilioli, Patrizia Barozzi, Leonardo Potenza, Roberto Marasca, Patrizia Comoli, Fabio Forghieri, Patrizia Zucchini, Tommaso Trenti, Daniela Vallerini, Monica Morselli
Rok vydání: 2017
Předmět:
Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
Filgrastim
030204 cardiovascular system & hematology
acute myeloid leukemia
Single Center
Biosimilars
filgrastim
autologous peripheral blood stem cell mobilization
acute myeloid leukemia
Transplantation
Autologous
03 medical and health sciences
Young Adult
0302 clinical medicine
Internal medicine
Hematologic Agents
medicine
Humans
Biosimilar Pharmaceuticals
Retrospective Studies
Biosimilars
Peripheral Blood Stem Cell Transplantation
business.industry
Myeloid leukemia
Biosimilar
Retrospective cohort study
Hematology
Middle Aged
medicine.disease
Hematopoietic Stem Cell Mobilization
Transplantation
Leukemia
autologous peripheral blood stem cell mobilization
Treatment Outcome
Leukemia
Myeloid
030220 oncology & carcinogenesis
Pharmacodynamics
Acute Disease
Peripheral Blood Stem Cells
Female
business
filgrastim
medicine.drug
Zdroj: Leukemialymphoma. 59(1)
ISSN: 1029-2403
Popis: Biosimilars of filgrastim have shown to be comparable to the originator (Neupogen®, Amgen Inc., CA) in terms of pharmacodynamic response in healthy subjects, as well as in overall efficacy and safe...
Databáze: OpenAIRE
Externí odkaz: